Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

21.49 (USD) • At close September 13, 2024
Bedrijfsnaam Arrowhead Pharmaceuticals, Inc.
Symbool ARWR
Munteenheid USD
Prijs 21.49
Beurswaarde 2,671,529,350
Dividendpercentage 0%
52-weken bereik 20.14 - 39.83
Industrie Biotechnology
Sector Healthcare
CEO Dr. Christopher R. Anzalone Ph.D.
Website https://arrowheadpharma.com

An error occurred while fetching data.

Over Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in

Vergelijkbare Aandelen

Surgery Partners, Inc. logo

Surgery Partners, Inc.

SGRY

31 USD

Novavax, Inc. logo

Novavax, Inc.

NVAX

13.61 USD

LivaNova PLC logo

LivaNova PLC

LIVN

48.53 USD

Natera, Inc. logo

Natera, Inc.

NTRA

126.51 USD

Guardant Health, Inc. logo

Guardant Health, Inc.

GH

26.79 USD

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

MMSI

96.16 USD

Amedisys, Inc. logo

Amedisys, Inc.

AMED

96.91 USD

CureVac N.V. logo

CureVac N.V.

CVAC

3.44 USD

Cerevel Therapeutics Holdings, Inc. logo

Cerevel Therapeutics Holdings, Inc.

CERE

44.96 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)